Saentra Forge

SAENTRA FORGE (Nasdaq: SAEN)

The Next-Generation Strategic Industrial Consolidator Focused on Aerospace, Defense, National Security — including physical AI, robotics, autonomous systems, advanced sensors, cybersecurity — and Biotechnology/Biosecurity.

November 2026

Saentra Forge

FORWARD-LOOKING STATEMENTS AND OTHER NOTICES

Statements in this presentation contain “forward-looking statements,” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this presentation are forward-looking statements. Forward-looking statements contained in this presentation may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “suggest,” “target,” “aim,” “should,” "will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Genenta Science S.p.A., doing business as Saentra Forge (the ”Company”) current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict, including risks related to the transition to Saentra Forge, the expansion to a sovereign-aligned industrial consolidator, the legal proceedings with ENEA Tech (Form 6-k filed on January 27, 2026), the funding provided by the recently acquired Mandatory Convertible Bond and related legal proceedings, clinical trial for newly diagnosed GBM patients, as well as the Company’s ability to raise capital and/or establish partnerships to fund its research and development plans, etc. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the Company's Annual Report on Form 20-F for the year ended December 31, 2025, and the Company's material disclosures on Form 6-K dated October 10, 2025, January 26, 2026, as well as other Form 6-K disclosures filed with the Securities and Exchange Commission. Forward-looking statements contained in this document are made as of the date of this announcement, and the Company undertakes no duty to update such information except as required under applicable law.

Non-GAAP Information. This document includes EBITDA (earnings before interest, taxes, depreciation, and amortization) which is a non-GAAP financial measure. EBITDA is defined as net loss adjusted to exclude interest income, income tax expense, and depreciation and amortization. This non-GAAP measure is not in accordance with, or an alternative for, measures prepared in accordance with generally accepted accounting principles (GAAP) and may be different from non-GAAP measures used by other companies. In addition, this non-GAAP measure is not based on any comprehensive set of accounting rules or principles. Saentra Forge believes that this non-GAAP financial measure, when considered together with financial information prepared in accordance with US GAAP, can enhance investors’ and analysts’ ability to meaningfully compare its results from period to period and to forward-looking guidance, and to identify operating trends in its business. However, non-GAAP information is not superior to financial measures calculated in accordance with GAAP, is presented for supplemental informational purposes only, has limitations as an analytical tool, and should not be considered in isolation or as a substitute for financial information presented in accordance with US GAAP. The Company is unable to provide a reconciliation of forward-looking EBITDA to the most directly comparable GAAP measure without unreasonable effort because certain items required for such reconciliation are outside the Company’s control and/or cannot be reasonably predicted.

Saentra Forge

SAENTRA FORGE

Saentra Forge[1] (**Nasdaq: SAEN**) is a **next-generation strategic industrial consolidator** focused on **acquiring majority or full ownership** of companies operating in security–regulated sectors, with activities spanning **aerospace, defense and national security — including physical AI, robotics, autonomous systems, advanced sensors and cybersecurity — as well as biotechnology and biosecurity**.

The Company seeks to acquire and retain profitable businesses operating in sectors covered by Italy's Golden Power legislation[2] and integrate them into a transparent, Nasdaq-listed platform. Its portfolio includes A.T.C. S.r.l., a wholly owned subsidiary, and Sòphia High Tech S.r.l., in which the Company holds a strategic investment with a contractual path to majority ownership through existing options.

1 – Saentra Forge is the business name of Genenta Science S.p.A. (Nasdaq: SAEN).
2 - Golden Power is Italy's investment screening framework — broadly comparable to CFIUS in the United States, the IEF regime in France, and the United Kingdom's NSI Act — and covers strategic domains such as biotechnology, biosecurity, defense, cybersecurity, AI-driven intelligence, aerospace, quantum technologies, secure communications, and critical infrastructure.

Saentra Forge

SAENTRA FORGE AT A GLANCE

2

Transactions completed in 2026

ATC (100%) and Sòphia High Tech (19.9%)

100%

ATC – wholly-owned subsidiary

Tactical defense systems · all-stock, May 2026

19.9%

Sòphia High Tech

Space & defense components · second tranche contemplated up to 51%

4

Strategic pillars

Aerospace · Defense · National Security · Biotechnology/Biosecurity

$33M

cash and marketable securities[1]

SAEN

Nasdaq-listed

American Depositary Shares

1 – December 31, 2025.

Saentra Forge

INDUSTRIAL CONSOLIDATOR


October 2025 – November 2026. Twelve months from strategy to execution: two transactions completed, governance strengthened, new identity adopted.



Saentra Forge

THE STRATEGIC PILLARS

Saentra Forge is organized around key synergistic pillars creating a diversified platform




AEROSPACE



DEFENSE



NATIONAL SECURITY




BIOTECHNOLOGY BIOSECURITY

Saentra Forge

A STRUCTURAL ADVANTAGE

In strategically regulated sectors, the barrier that deters most buyers is our entry point – not an obstacle, but a moat.



1 THE FILTER

Golden Power screens every acquisition in strategic sectors. For foreign strategic buyers and traditional private equity it is a barrier: transactions blocked, conditioned or delayed.

2 THE RIGHT PROFILE

Italian, Nasdaq-listed, with sovereignty-aligned governance: Fondazione Praexidia[1] is a long-term shareholder with consultation rights and a renewable five-year lock-up. This is what clears the filter.

3 PROTECTED ASSETS


Acquired companies stay in Italian hands, consolidated and held long-term within a transparent listed platform – the alternative to a sale abroad.

1: Fondazione Praexidia is a private-law foundation bringing together senior figures from Italian government institutions, the defense industry and the armed forces; Source: Form 6-K filed January 27, 2026.

Saentra Forge

WHY NOW: THE OPPORTUNITY

Italy's defense supply chain is a vast, fragmented base of SMEs – the headline figures capture only the tip



~28	avg. employees per firm (vs 10 in manufacturing) — small, specialized[5]
+5%	supply-chain sales growth in 2025, above manufacturing[5]
≈€12.2B	additional Italian defense spend planned by 2028 (+~0.5pp of GDP)[5]

Everyone quotes the tip. Saentra Forge's opportunity is the fragmented base — thousands of specialized SMEs to consolidate.

2: Mediobanca Area Studi, "Sistema Difesa nel mondo e in Italia," 2024 edition (FY2023 data).
5: Banca d'Italia, Annual Report 2025, box "La difesa in Italia" (FY2023 data; 2025 Invind survey).

Saentra Forge

WHY NOW: THE OPPORTUNITY

Sellers in strategic sectors have fewer exit routes just as capital and demand surge into the sector
Saentra Forge can act on these opportunities: the right profile to clear the filter, and a listed currency to pay for them.

THE SUPPLY — SELLERS WITH FEWER EXIT ROUTES

36/100	Top 100 defense firms foreign-controlled — 25.1% of sector revenue[2]
~2/3	of Italian PE exits since 2000 saw control pass to foreign buyers[1]
EXIT	PE sells on a fixed clock; with Golden Power screening foreign buyers, founders need a domestic, long-term alternative

THE TAILWIND — CAPITAL & DEMAND ARRIVING

~$8.7B	European DSR venture funding in 2025, up 55% YoY[3]
Up to €800B	EU resources under ReArm Europe / Readiness 2030[4]
+5%	Italian supply-chain sales in 2025; ~+0.5pp GDP defense spend by 2028[5]

THE OPPORTUNITY — SAENTRA FORGE, CONSOLIDATOR OF THE STRATEGIC SUPPLY CHAIN

Saentra Forge acquires profitable SMEs at private-market valuations, from sellers whose alternative buyers are screened out, and consolidates them within a transparent, Nasdaq-listed platform — long-term ownership, no forced exit.

The value is here, and the buyers who can access it are few — that is the opportunity Saentra Forge is built to capture.


1: Fondazione Praexidia–Banca Investis study (2026). 2: Mediobanca Area Studi, 2024 edition (FY2023). 3: Dealroom & NATO Innovation Fund, 2025 full-year.
4: European Commission, ReArm Europe / Readiness 2030 (2025); targets, not committed spending. 5: Banca d'Italia, Annual Report 2025, box "La difesa in Italia."

Saentra Forge

ACQUISITION CRITERIA

A disciplined filter applied to strategic scale-up –
acquiring where private capital wants in but cannot easily access.

THE PIPELINE



THE FILTER

01 MAJORITY CONTROL
Targeting 51%+ ownership — full strategic control, not minority stakes.

02 ESTABLISHED PROFITABILITY
Positive operating profile, typically up to ~€5M EBITDA.

03 PRIVATELY HELD
Italian founder- and family-owned businesses facing a scale-up gap.

04 GOLDEN POWER SECTORS
Defense · Aerospace · Cybersecurity · Biotech / Biosecurity.

05 PRIVATE-MARKET VALUATIONS
Acquired at private-market prices, integrated into a Nasdaq-listed platform.

Saentra Forge

VALUE CREATION PLAYBOOK

Acquire at private-market valuations, consolidate within a Nasdaq-listed platform, hold long-term. Value is created after closing.

GOVERNANCE & REPORTING

- Board of Directors with Saentra Forge representation
- Institutional-grade controls and SEC-aligned reporting
- Group finance integration

In practice: ATC: Board strengthened with Paolo Salvato (Feb 2026). Sòphia HT: new Board with Saentra Forge directors and observer (Jul 2026).

ACCESS TO CAPITAL

- Nasdaq listing as a source of growth funding
- Shares as acquisition currency, preserving cash
- Performance-driven tranches aligned to milestones

In practice: ATC (May 2026). Sòphia HT: performance-driven second tranche to 51%.

INSTITUTIONAL NETWORK

- Fondazione Praexidia: institutions, defense industry, armed forces
- Sovereignty-aligned governance facilitates Golden Power clearance
- Access to programs and counterparties

In practice: Golden Power clearance obtained for both ATC and Sòphia HT.

COMMERCIAL & INTERNATIONAL GROWTH

- Production capacity and technological differentiation
- Export markets and institutional customers
- Cross-selling across the group

In practice: Sòphia HT proceeds allocated to capacity, differentiation and commercial penetration.

The result: private-market entry, public-market visibility. Companies are held long-term; value is reflected through the Nasdaq-listed platform rather than through a forced exit.

LEADERSHIP



PIERLUIGI PARACCHI

Chairman, CEO & Founder

He serves also as Chairman of **Fondazione Praexidia** and Chairman of **Praexidia Industrie Strategiche** (Euronext: PRXD). He is also Moderator of the **National Working Table for the Internationalization of the Biotechnology Sector**, promoted by the Italian Ministry of Foreign Affairs.

He serves on the Board of Guarantors of the **Italian Academy at Columbia University.**

Previously, he founded and led **Quantica SGR**, co-founded **Axòn Capital**, and served as Venture Consultant at **Sofinnova Partners.** He has also served on the Executive Committee of Federchimica–Assobiotec and is a Board Member of **InnovUp.**

+ 30 years of experience as Chief Financial Officer in various biopharmaceutical, diagnostic, and life science companies, including **Biological Dynamics**, **GenMark Diagnostics** (now part of Roche), and **C-N Biosciences** (now part of Merck). He also serves on the Board of Directors of several private high-technology companies, including **Nuclear RNA Networks**, an early-stage RNA gene transcription therapeutics company, and **Parabilis Space Technologies**, a global leader in hybrid solid-liquid rocket motors shaping the next era of responsive space operations. Raised $500MM+ in equity and debt capital in public and private offerings. He holds a B.S. from the University of Pennsylvania (Wharton School), MBA from the University of Arizona (Eller School).

RICHARD B. SLANSKY

Chief Financial Officer





BARBARA REGONINI

VP Finance & Group Integration

Highly experienced executive with skills in strategic finance, restructuring and reorganization processes, internal controls and corporate governance systems implementation. Prior to joining the Company, she was Head of Finance at **OAM** – Financial Supervisory Authority, and she held CFO roles and was part of the Supervisory Body ex DLGS 231/01 of a public company in the renewable energy field. Former senior manager at **PWC**, in the industrial and service field. She earned a Master's degree at the University of Nicosia in Science of Digital Currency, a Degree as Strategic CFO at Harvard Business School, a Master's degree in Business and Administration at the University of Parma and she is a Chartered Public Accountant and Auditor.

Educated at Bocconi University and the London School of Economics, he began his career as an Equity Analyst Intern at **Kairos Partners SGR – Julius Baer Group**, before moving into investment banking at **NM Rothschild & Sons**. He subsequently gained experience in private banking and wealth management at **Mediobanca**, **Banor SIM and Banca Generali**. Since 2023, he has served as Vice President Corporate Development where he manages relationships with global institutional investors, investment banks and analysts, partnering directly with the CEO.


GIANFRANCO DE NIGRIS

Vice President Corporate Development




Note: Francesco Galimi, M.D., Ph.D., is a Board Member and serving as Chief Medical Officer and Head of Development

Saentra Forge



- AEROSPACE
- DEFENSE

Saentra Forge




WHY SPACE, WHY NOW: THE STRATEGIC RATIONALE

The space economy is scaling rapidly, driven by commercial demand, national security priority, and sovereign investment

ORBITAL LAUNCHES — 2025 YEAR IN REVIEW

325	4,544	87%	2.7M kg
orbital launches worldwide in 2025	spacecraft deployed in 2025	of launches conducted by commercial providers	of spacecraft mass launched (est.)
+25% vs 2024	+54% vs 2024		

2025 VS 2024



LONG-TERM DEMAND DRIVERS

- Commercial satellite constellation expansion
- Defense and national security demand
- Sovereign investment in strategic space capabilities
- Growing need for specialized manufacturing capacity

Every rocket launched, every satellite deployed and every next-generation defense platform depends on a highly specialized manufacturing supply chain.

That is where Sòphia High Tech operates.


WHY SÒPHIA HIGH TECH

Sòphia High Tech designs and manufactures flight-qualified critical mechanical components for space and defense systems, serving ESA, Avio, Thales Alenia Space, Leonardo and MBDA. Through its strategic investment in Sòphia, **Saentra Forge** gains exposure to a growing segment of Europe's strategic industrial base.

Source: BryceTech, Orbital Launches Year in Review 2025. 2024 values (≈) are implied from BryceTech's reported growth rates. Commercial share refers to launches conducted by commercial providers. Sòphia High Tech information: company materials.

Saentra Forge

SOPHIA HIGH TECH: COMPANY OVERVIEW



What it does

- Builds the **critical mechanical components** of space and defense systems, precision parts that hold rockets together, protect satellites in orbit, and let aircraft perform under extreme stress. Covers the **entire product lifecycle:** concept design & simulation → prototyping → manufacturing → testing, assembly & flight qualification.

What sets it apart

- Mastery of **space manufacturing:** metal 3D printing (Selective Laser Melting), CNC precision machining & multitasking.
- **Advanced materials** (titanium, Inconel, tungsten, specialized copper alloys) plus proprietary new alloy R&D for space propulsion.


Certifications & credentials

- **EN9100** (aerospace quality) and **ECSS-Q-ST-70-80C** (ESA additive-manufacturing spec).
- One of the very few companies in Europe qualified to **3D-print flight-ready space hardware to ESA and NASA standards.**

Track record

- **530+ advanced projects completed.**
- Customers: **ESA, AVIO, Thales Alenia Space, Leonardo, MBDA, GSSI, D-Orbit,** plus prestigious automotive brands such as **Lamborghini.**

SOPHIA HT: KEY FIGURES



The transaction

- April 22, 2026 — Saentra Forge signed an Investment Agreement with Sòphia HT to reach a controlling stake through a phased two-tranche structure.
- June 12, 2026 — Required Golden Power authorization obtained.
- June 25, 2026 — First tranche completed following satisfaction of all closing conditions; Saentra Forge now holds 19.9% of Sòphia HT.

Structure & funding

- Total funding of € 6.0M in two tranches[1] — the second tranche performance-driven taking Saentra Forge to 51%.
- Proceeds to scale production capacity, accelerate technological differentiation, and strengthen commercial penetration.


Financial profile

- Already profitable, with a solid net cash position and disciplined management. FY2025: €8.47M Total Operating Revenues, €1.61M EBITDA, 19.0% margin. Total value of production, including €7.17M sales and €1.30M other operating income[2].
- Projecting growing revenues and continued EBITDA growth in 2026, 2027 and beyond[3].

1: See "Non-GAAP Information" for a discussion of the measure EBITDA 2: Unaudited, provided by Sòphia HT, not consolidated 3: For additional information, please refer to our Form 6-K, filed with the Securities and Exchange Commission. Based on management estimates and current order pipeline; not audited; subject to execution, production capacity, customer timing, export authorizations, geopolitical developments and other risks described in the Company's SEC filings.


Saentra Forge

SPACE MANUFACTURING & CUSTOMERS





DEFENSE MARKET CONTEXT




DEFENSE MARKET CONTEXT

THE DEFENSE INDUSTRIAL BASE IS EXPANDING STRUCTURALLY

Global military spending is supported by sustained geopolitical priorities, long-term NATO commitments and large-scale European industrial investment.

GLOBAL MILITARY EXPENDITURE (US$ TRILLION)

Current US$, as published by SIPRI each year



$2.89T
global military expenditure in 2025

11
consecutive years of growth

+2.9%
real-terms increase in 2025

Source: SIPRI

Source: SIPRI Military Expenditure Database, Trends in World Military Expenditure fact sheets (April 2021–April 2026), world totals in current US$ as published each year. The +46% figure is nominal; SIPRI reports real growth of 41% over 2016–2025.

LONG-TERM STRUCTURAL DRIVERS

5% of GDP

NATO Allies committed to invest 5% of GDP annually in core defense and defense- and security-related spending by 2035 (3.5% + 1.5%)

Source: NATO, The Hague Summit Declaration, June 25, 2025

Up to €800B


ReArm Europe Plan / Readiness 2030: EU plan to mobilise up to €800 billion in defense spending by 2030 (national fiscal flexibility plus €150 billion SAFE loans)

Source: European Commission, March 2025

Defense budgets create value only once they translate into industrial production capacity. Companies with certified manufacturing capabilities are positioned to benefit from this long-term investment cycle.
ATC, a wholly-owned subsidiary, gives **Saentra Forge** direct exposure to this specialized manufacturing layer of the defense industrial base.

Saentra Forge


ATC: COMPANY OVERVIEW



- ATC "Armi Tattiche Custom" is an Italian company **founded in 2019.** ATC designs, engineers, and manufactures **high-precision tactical rifles, chassis systems, optics mounts, bipods, and related accessories.** Through vertical integration of design and through final quality assurance, ATC provides fully customized, premium tactical systems. Its location in Northern Italy gives it access to advanced mechanical engineering talent and streamlined export logistics.
- ATC conducts its core operations in Italy, including R&D, CAD/CAM design, precision CNC machining, finishing, assembly, and final tomographic inspection.
- ATC holds UAMA, SeRNI export-control licenses, NATO qualifications and authorization from the Italian Ministry of Defense[1].
- ATC products are used by special-forces units and include **combat-proven systems.** FY26 revenues are expected to be primarily driven by defense-related activities, including contracts with key institutional customers, notably in Ukraine.


1: UAMA is the Italian government authority responsible for authorizing and overseeing the export and transfer of defense-related materials under applicable Italian and international regulations.
SeRNI the Italian National Register of Defense and National Security Companies, certifies authorized defense and national security operators.

ATC: THE ACQUISITION



- **Timing:** January 2026 - Initial investment agreement signed. May 2026 - Saentra Forge completed the acquisition of 100% of A.T.C. S.r.l. ("ATC") through newly issued Saentra Forge shares, preserving corporate liquidity and financial flexibility for future strategic investments and acquisitions.
- **Long-term alignment through a 36-month lock-up**
  Former ATC shareholders are subject to a three-year lock-up, aligning their economic interests with long-term value creation and eliminating near-term selling pressure following closing.
- **Entrepreneurs become long-term shareholders**
  Rather than monetizing their business for cash, the former owners have reinvested 100% of their proceeds into Saentra Forge equity, demonstrating confidence in the long-term value creation potential of the broader industrial platform.
- **Structured downside protection without near-term capital commitment**
  A put option becomes exercisable only between the third and fifth anniversaries of closing, and only if the share price remains materially below the agreed reference value, limiting short-term financial exposure while providing long-term alignment.
- **Embedded upside through a highly favorable call option**
  If Saentra Forge's share price appreciates materially, the Company retains the right to reacquire the issued shares at a predetermined price, allowing shareholders to benefit from future value creation while limiting dilution over time.
- **Disciplined transaction structure**
  The transaction was completed through a fixed-value, stock-for-stock exchange with no earn-outs or purchase-price adjustments, providing execution certainty, simplified integration and clear economic alignment from day one.

Saentra Forge



BIOTECHNOLOGY BIOSECURITY

Saentra Forge

BIOTECHNOLOGY: A PARTNERSHIP-DRIVEN PILLAR

A proprietary cell-therapy platform with clinical proof of concept, advanced through partnerships rather than Company-funded development.

TEM-GBM PHASE 1/2a STUDY

25	patients dosed with Temferon™; Phase 1 dosing completed
76% · 32%	alive at 1 and 2 years from first surgery (vs 56.4% · 14.4% registry reference)[1]
2	patients beyond 3 years, enrolled in long-term follow-up
0	dose-limiting toxicities observed to date

THE PLATFORM

Temferon™ is a one-time cell therapy designed to break tumor-induced immune suppression through sustained, targeted expression of a therapeutic payload inside the tumor microenvironment. Preliminary data in glioblastoma show a manageable safety profile, Temferon-derived cells detectable beyond 24 months and reprogramming of the tumor microenvironment.

THE STRATEGY





Partnership-driven: the Company does not plan to incur material additional clinical-development costs unless supported by a strategic partner or dedicated external financing. DC Advisory is engaged as exclusive financial advisor; to date no partner has been identified and no active discussions are ongoing[2].

CURRENT STATUS

The GBM clinical trial remains active and is supported and monitored by the Company. The amended and restated license agreement with Ospedale San Raffaele was terminated following Board approval (May 2026), with no material termination fee expected other than accrued obligations[3].

1 – Data as of January 20, 2026; registry reference: Istituto Nazionale Carlo Besta, courtesy of Dr. Eoli. Temferon™ is an investigational product candidate; effectiveness and safety have not been established and it is not approved in any jurisdiction. Clinical data remain subject to adjustment until finalized in a clinical study report.
2 – Form 6-K filed March 24, 2026. 3 – Form 6-K filed May 19, 2026. Full clinical data: see Appendix.
Note: www.saentra.com for more information.

Saentra Forge

PIERLUIGI PARACCHI, CEO

pierluigi.paracchi@saentra.com

Saentra Forge

www.saentra.com

Saentra Forge

APPENDIX

Saentra Forge

BOARD OF DIRECTORS



PIERLUIGI PARACCHI

Chairman, CEO & Founder

He serves also as Chairman of **Fondazione Praexidia** and Chairman of **Praexidia Industrie Strategiche** (Euronext: PRXD). He is also Moderator of the **National Working Table for the Internationalization of the Biotechnology Sector**, promoted by the Italian Ministry of Foreign Affairs.

He serves on the Board of Guarantors of the **Italian Academy at Columbia University**.
Previously, he founded and led **Quantica SGR**, co-founded **Axòn Capital**, and served as Venture Consultant at **Sofinnova Partners**. He has also served on the Executive Committee of Federchimica–Assobiotec and is a Board Member of **InnovUp**.

Dr. Galimi is a physician-executive with over 30 years of experience in healthcare R&D, including leadership roles in private and public biotechs as well as large pharma companies.

Most recently, he was Senior Vice President and Chief Medical Officer at **Adicet Bio**.

Previously he served as Global Program General Manager at **Amgen**, Head of Clinical Development at **Onyx Pharmaceuticals**, and Executive Medical Leader at GNF/Novartis.

Dr. Galimi holds an M.D. from the University of Torino Medical School with a specialty certification in Medical Oncology, and a Ph.D. in Oncology from the University of Torino Medical School. He conducted his post-doctoral research at the Salk Institute in La Jolla, California.

FRANCESCO GALIMI

M.D., Ph.D., Board Member, serving as Chief Medical Officer and Head of Development





MIGUEL M. MUTTI

Board member

Senior executive with over 25 years of international experience in the pharmaceutical and investment banking sectors. He has a proven track record in corporate and business development, M&A, licensing, and general management, having led major growth, restructuring, and integration projects across Europe, Latin America, and Asia.

Currently, he serves as Managing Partner at **Sinergetica Healthcare**, a strategic consulting and investment firm focused on pharma, biotech, and medtech. Before that, he held senior leadership roles at **Lupin Limited, Grünenthal GmbH, Chemo Group, and Citigroup.**

Miguel combines strategic vision, financial expertise, and hands-on operational leadership, supported by an MBA from ISTUD and executive training at INSEAD.

Giacomo Paracchi is a **Partner** at **LEXIA.**
His work primarily focuses on corporate law, commercial contracts and corporate governance, drawing on extensive experience both as a non-practising attorney and as **General Counsel** to major public and private multinational companies.
He has developed significant expertise across a wide range of industry sectors, including telecommunications, logistics, infrastructure, oil & gas, energy, pharmaceuticals and biotechnology.
Giacomo is a member of the **Advisory Board** of the **Università Cattolica del Sacro Cuore** (Milan) for the **Executive Advanced Training programme in Corporate Compliance & Business Integrity**.

GIACOMO PARACCHI

Board member





ARMON R. SHAREI

Ph.D., Board Member

Armon is Founder and CEO of **Portal Biotechnologies** and formerly CEO and Founder of **SQZ Biotechnologies** (NYSE: SQZ).

He led company from invention to post-IPO with over $300M in equity financing, $1Bn **Roche** collaboration, and three clinical trials.
Stanford University, CA BS, with Honors and Distinction in Chemical Engineering and a Ph.D. in Chemical Engineering from Massachusetts Institute of Technology.
Post-Doctoral Fellow, Immunology at Harvard Medical School.

Saentra Forge

FINANCIAL PROFILE





Cash & cash equivalents and marketable securities[1]	$ 33 MM
Expected cash runway[2]	More than 12 months
Number of shares outstanding[3]	48.2 MM
Average daily volume[4]	1.5 MM shares

1 – December 31, 2025.
2 – For additional information see the Company's Form 20-F filed with the SEC on March 31, 2026.
3 – As of May 29, 2026.
4 - At July 1, 2026 according to Yahoo Finance's key statistics listing.

Saentra Forge

PARTNERSHIPS TO TAKE TO THE NEXT STAGE



PARTNERSHIPS TO TAKE TO THE NEXT STAGE

The Company has reached key clinical milestones that it believes may enable the advancement of its cell therapy platform through partnerships with leading pharmaceutical and biotech companies, with the potential to accelerate development, market access, and strategic value. The Company has for some time been engaged with DC Advisory as its exclusive financial advisor to explore partnership opportunities for its biotechnology platform. To date, DC Advisory has not identified, and the Company is not in active discussions with, any potential strategic partner regarding Temferon or the platform; the Company nevertheless intends to continue pursuing such opportunities in light of the quality of the underlying science and the preliminary clinical data generated to date. The Company continues to support and monitor its GBM clinical trial, which remains active, while pursuing a capital-efficient approach to advancing additional opportunities through partnerships. The Company has shifted its biotech strategy to a partnership-driven model and does not plan to incur material additional clinical development costs unless supported by a strategic partner or dedicated external financing. As disclosed in the Company's relevant Form 6-K[1], the Board approved the termination of the Company's amended and restated license agreement with Ospedale San Raffaele (OSR), following a review of its strategic priorities and resource allocation, with no material termination fee or penalty expected other than accrued obligations.

1 – May 19, 2026.

Saentra Forge

POTENTIAL FIRST IN CLASS CELL THERAPY



Proprietary platform to provide durable and safe treatments for solid tumors

Temferon ™ is a one-time cell therapy designed to break the tumor-induced immune suppression by enabling sustained targeted expression of **therapeutic payload inside the tumor microenvironment (TME).**



Generating clinical proof of concept for breaking immune tolerance

TEM GBM Phase 1/2a study:

- **Phase 1 dosing completed** with 25 patients receiving Temferon.
- Favorable initial evidence of reprogramming of the tumor microenvironment.
- Potential ability to activate T cells which could then be enhanced by the use of immune checkpoint inhibitors.
- **Two patients** have been enrolled in the **TEM-LT long-term follow-up study, surviving three years** from the time of 1st surgery.

Saentra Forge

SURVIVAL METRICS IN TEM-GBM STUDY UP TO 3 YEARS

Evaluable Patients Dosed with Temferon	25
Number of Patients survival > 1 year	19 (76%)
Number of Patients survival > 2 years[1]	8 (32%)
Number of Patients survival > 3 years	2 (8%)

Survival rate at 1 and 2 years since first surgery compared favorably with reference GBM Italian registry data[2] (56.4% alive at 1 year, 14.4% alive at 2 years), indicating a potential survival benefit in the TEM-GBM treated cohort.

1 – Data as of January 20, 2026.

2 – Tumor registry of Istituto Nazionale Carlo Besta, Italy - Courtesy of Dr. Eoli.

Saentra Forge

PRELIMINARY CLINICAL DATA IN µMGMT GBM

SAFETY AND TOLERABILITY

- Detectable and expectedly very **low levels of IFN-α** (pg/ml range) in plasma;
- **Manageable safety profile,** with adverse events commonly associated with autologous stem cell transplantation and glioblastoma;
- **No dose limiting toxicities** observed to date;
- Rapid engraftment and **hematological recovery** observed in all patients treated (n=25).

BIOLOGICAL ACTIVITY

- Temferon-derived cells were **detectable** at more than 24 months **post infusion;**
- **Temferon** progeny detected **inside the GBM** tumor;
- Intra-tumor **IFN-α release;**
- Evidence of a pro-inflammatory state in recurrent tumors from patients who underwent second surgery;
- **Reprogramming** of the myeloid compartment.